For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG-ACRIN EA5162

Trial Overview

Official Title

Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose

To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.

Diagnosis

Stage IIIB or IV advanced non-small cell lung cancer with EGFR exon 20 insertion mutation.

Eligibility

ECOG performance status 0 or 1.

Documentation of EGFR exon 20 insertion mutation.

Must have had at least one prior treatment for advanced and/or metastatic lung cancer-may have received more than 1 treatment.

Must have disease that is measurable by CT scan.

No prior treatment with therapies targeting PDL-1 or PD1 or CTLA4.

Normal organ and bone marrow function.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Osimertinib 160 mg orally every day.
  • Cycle 21 days
  • CT scans for response every 6 weeks.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Suspended
Phase
Phase II
Methodist Health System Trial Code
EA5162
Related Specialties